Astrazeneca (AZN) Non-Current Receivables (2016 - 2025)
Astrazeneca (AZN) has 3 years of Non-Current Receivables data on record, last reported at $1.4 billion in Q4 2025.
- For Q4 2025, Non-Current Receivables rose 49.57% year-over-year to $1.4 billion; the TTM value through Dec 2025 reached $1.4 billion, up 49.57%, while the annual FY2025 figure was $1.4 billion, 49.57% up from the prior year.
- Non-Current Receivables reached $1.4 billion in Q4 2025 per AZN's latest filing, up from $930.0 million in the prior quarter.
- Across five years, Non-Current Receivables topped out at $1.4 billion in Q4 2025 and bottomed at $803.0 million in Q4 2023.
- Average Non-Current Receivables over 3 years is $1.0 billion, with a median of $930.0 million recorded in 2024.
- Peak YoY movement for Non-Current Receivables: increased 15.82% in 2024, then soared 49.57% in 2025.
- A 3-year view of Non-Current Receivables shows it stood at $803.0 million in 2023, then grew by 15.82% to $930.0 million in 2024, then skyrocketed by 49.57% to $1.4 billion in 2025.
- Per Business Quant database, its latest 3 readings for Non-Current Receivables were $1.4 billion in Q4 2025, $930.0 million in Q4 2024, and $803.0 million in Q4 2023.